MARKET

PRAX

PRAX

Praxis Precision Medicines, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.010
+0.080
+2.04%
Closed 17:10 08/09 EDT
OPEN
3.910
PREV CLOSE
3.930
HIGH
4.030
LOW
3.591
VOLUME
767.37K
TURNOVER
--
52 WEEK HIGH
23.56
52 WEEK LOW
1.630
MARKET CAP
182.50M
P/E (TTM)
-0.8552
1D
5D
1M
3M
1Y
5Y
Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Praxis Precision Medicines press release (<span class...
Seekingalpha · 1d ago
Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by...
GlobeNewswire · 6d ago
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. 
Benzinga · 07/11 18:20
ICVX, MAPS, TCMD and AVAV among after hour movers
Gainers: Tactile Systems Technology (TCMD) +4.9%. Roth CH Acquisition (ROCC) +4.9%. Hertz Global Holdings (HTZ) +4.8%. WM Technology (MAPS) +4.7%. LendingTree (TREE) +4%. Losers: Icosavax (ICVX) -22.0%. AeroVironment (AVAV) -10.1%. Playa Hotels
Seekingalpha · 06/28 21:27
Insiders at Praxis Precision Medicines, Inc. (NASDAQ:PRAX) recouped some losses this week after buying this year, still down US$156k
Insiders who bought US$357k worth of Praxis Precision Medicines, Inc. ( NASDAQ:PRAX ) stock in the last year have seen...
Simply Wall St. · 06/26 13:47
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 84 companies set new 52-week lows.
Benzinga · 06/09 17:21
Piper Sandler Adjusts Price Target on Praxis Precision Medicines to $18 From $65, Reiterates Overweight Rating
MT Newswires · 06/08 04:52
CTSO, LIDR and UONE among mid-day movers
Gainers: Aero Clean Technologies (AERC) +49%. Houston American Energy (HUSA) +37%. Jan One (JAN) +37%. Oncorus (ONCR) +41%. Cytosorbents  (CTSO) +33%. Mirati Therapeutics (MRTX) +30%. Omega (OMGA) +27%. Codiak BioSciences (CDAK) +27%. Quantum
Seekingalpha · 06/07 17:10
More
No Data
Learn about the latest financial forecast of PRAX. Analyze the recent business situations of Praxis Precision Medicines, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
50.00%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRAX stock price target is 9.00 with a high estimate of 18.00 and a low estimate of 4.000.
High18.00
Average9.00
Low4.000
Current 4.010
EPS
Actual
Estimate
-1.21-0.91-0.60-0.30
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 108
Institutional Holdings: 58.99M
% Owned: 129.62%
Shares Outstanding: 45.51M
TypeInstitutionsShares
Increased
39
2.08M
New
14
164.69K
Decreased
26
381.85K
Sold Out
10
250.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Non-Executive Chairman/Independent Director
Dean Mitchell
President/Chief Executive Officer/Director
Marcio Souza
Chief Financial Officer
Timothy Kelly
General Counsel/Secretary
Alex Nemiroff
Other
Nicole Sweeny
Independent Director
Jeffrey Chodakewitz
Independent Director
Merit Cudkowicz
Independent Director
Jill Desimone
Independent Director
Gregory Norden
Independent Director
Stefan Vitorovic
Independent Director
William Young
No Data
No Data
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating genetic insights into the development of therapies for central nervous system (CNS) disorders. Its portfolio of CNS programs is structured by therapeutic focus in three primary franchises, which include Psychiatry, Movement Disorders, and Epilepsy. It has three product candidates, which include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extra synaptic gamma-aminobutyric acid-A (GABAA) receptor preferring positive allosteric modulator (PAM) for the treatment of a range of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channels developed for the treatment of Essential Tremor (ET) and Parkinson's Disease(PD). PRAX-114 is developed for the treatment of a range of patients suffering from post-traumatic stress disorder (PTSD).

Webull offers kinds of Praxis Precision Medicines Inc stock information, including NASDAQ:PRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRAX stock methods without spending real money on the virtual paper trading platform.